Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Dublin, March 08, 2017 -- Research and Markets has announced the addition of the "The World Market for Personalized Medicine Tests for Cancer" report to their offering.
Personalized Medicine Tests for Cancer, provides an authoritative look at the market for companion and personalized medicine testing for cancer. The report includes a market size and forecast for personalized medicine testing by geography (US, EU, ROW). Company profiles are included and products are identified by status (on the market, in development)
Key Topics Covered:
Chapter One Executive Summary
- The Scourge of Cancer
- Definitions of Companion Diagnostics and Cancer Diagnostics
- Types of Tests Included
- Marketing Personalized Medicine-Based Cancer Tests
- Market
- Point of View
Chapter Two Introduction
- Cancer Treatments
- Cancer Risk Assessment
- Cancer Screening
- Cancer Monitoring
- Prognosis Assessment
- Technologies Used
- Immunoassays
- Immunohistochemistry (IHC)
- Flow Cytometry
- In Situ Hybridization
- Nucleic Acid Amplification Technologies
- Analysis of Gene Expression Patterns (Gene Signatures)
- Microarrays
- Sequencing Technologies
- Mass Spectrometry
- Liquid Biopsies
- Information Technology
- Test Targets
- HER2 Overexspression
- EGFR
- KRAS Mutations
- BRAF Mutations
- UGT1A1 Genetic Variants
- 5-Flurouracil Therapy
- PIK3CA Mutations
- KIF6 Mutations
- ALK Mutations
Chapter Three Market Analysis
- Products on the Market
- Market Analysis
- Drivers
- Diagnostic Companies and Pharmaceutical Companies
- Growth by Geography
Chapter Four Company Profiles.
- 20/20 GeneSystems, Inc.
- Abbott Laboratories
- ACT Genomics Co., Ltd.
- Adaptive Biotechnologies Corporation
- Admera Health (A GENEWIZ Company)
- Agena Bioscience Inc.
- Agendia NV
- Amoy Diagnostics Co., Ltd.
- ARKRAY, Inc.
- Biocartis
- bioMérieux SA
- Cepheid (Danaher)
- Genomic Health, Inc.
- Genoptix (A Novartis Company)
- Luminex Corporation
- Myriad Genetics, Inc.
- Qiagen N.V.
- QuanDx Inc.
- Quest Diagnostics
- Qvella Corporation
- RiboMed Biotechnologies, Inc.
- Roche
- Siemens Healthcare
- Symbiodx
- Theranostics Health Inc. (Acquired by Avant Diagnostics, Inc.)
- Thermo Fisher Scientific, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/778jp3/the_world_market
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Genomics, Diagnostics, Oncology Drugs
